Company

• Overview

• Board of Directors

• Partnering

• Core competence

Technology

• Glycan-specific Conjugation

• Alphatecan

• Bispecific Antibody

• Subcutaneous Formulation

• Single-domain Antibody

• Publications

Pipeline

• Overview

• Envafolimab(KN035)

• KN026

• JSKN003

• JSKN016

• JSKN033

• KN046

• KN019

Investors

• Information Disclosure

• Corporate Governance

• Stock Information

• Corporate Communications

• Email Subscription

News

• Press Release

• Media Report

Career

• Corporate Culture

• Job Opportunities

Contact Us